Cramer Recommends J&J For Best Big Pharma Pipeline Play

Coming out of the Twittersphere Wednesday afternoon: a trader asks Jim Cramer about a potential big pharma play which could fit into his or her portfolio. The trader specified the play would need to be for over the next five years. Cramer responded: J&J JNJ shares do not seem to be responding to the recommendation by Cramer, but are trading at afternoon highs. The stock is down 0.6 percent to $92.74 at last check.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsJim CramerMediaTrading Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!